The centres, one in New Jersey for sterile and speciality drugs, one in San Antonio for liquid and semi-solid forms and a third, also in San Antonio, for R&D and formulation development create specialist hubs that DPT believes benefit customers.
The company spokesman said that: “Our new alignment reflects our focus on specific client needs and the ability to provide customer service from personnel who are experts within a specialized area.”
Despite the move, he continued, the contract development and manufacturing organisation (CDMO) is still a “one stop shop,” explaining that: “We’re simply providing specialized manufacturing services at two sites, due to the requirements for providing semi-solid and liquid manufacturing under cGMP and sterile conditions.
“The separation of sterile and semi-solid and liquid manufacturing will increase overall efficiencies for the company,” he continued, adding that DPT is dedicated to further improving the functioning of the new units.
“Our focus right now is to optimize our Centers of Excellence to better serve our customers. We plan to make ongoing facility enhancements as we continue to grow.”
pMDIs and aseptic capacity
In addition to restructuring its development and manufacturing operations DPT has also invested to add new specialist capacities at the three centres.
The semi-solids and liquids unit, for example, now has extra capacity for the production of aerosols and pressurized metered dose inhaler (pMDI) for clinical trials and commercial supply.
Additionally, the 175,000 sq ft New Jersey sterile products facility recently had “a multimillion dollar transformation,” according to DPT, which included the installation of new aseptic processing suites and filling equipment.